Merck & Co., Inc. has reported a strong financial performance with a market cap of $307.3 billion and a 23.5% increase in stock over the past three months, earning a 'Moderate Buy' consensus from analysts. However, the pharmaceutical company is bracing for the impact of Keytruda's patent expiration in December 2028, which currently generates over 50% of its sales. In response, Merck has restructured its operations into Oncology and Specialty/Pharma & Infectious Diseases, aiming to mitigate potential revenue declines of up to 50% and maintain a robust pipeline with over 30 active studies across various cancers.
“Merck & Co., Inc. (MRK) · has a market cap of · $307.3 billion”
“Merck & Co. (MRK) · is classified as · mega-cap · true”
“Merck & Co. (MRK) · stock has increased · 23.5% · over the past three months”
“MRK stock · is up · 17.8% · on a YTD basis”
“Shares of MRK · rose · 2.2% · on Feb. 3”
“MRK stock · has a consensus rating of · Moderate Buy · from 28 analysts”
“Merck (MRK) · said · phase 3 trial · showed Keytruda plus Padcev decreased the risk of event”
“Merck & Co. Inc. · has volume · 17,531,094”
“Merck · is a Dow stock · that has a healthy record of dividend growth · true”
“Merck · is rated · Outperform · true”
“Merck · has a price target of · $142 · true”
“Merck & Co. Inc. · Last · price · 123.82”
